FOLH1 and prostate cancer: Since prostate-specific membrane antigen (PSMA) is secreted from the majority of prostate cancer (PCa) cells and tumor-associated neo-vasculatures, antiangiogenic and anti-tumor effects can presumably deal with PSMA-CARs (NCT00664196) (66).